BridgeBio Oncology Therapeutics, Inc. Cash Flow Conversion Efficiency
BridgeBio Oncology Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has a cash flow conversion efficiency ratio of -0.096x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.92 Million) by net assets ($372.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Cash flow conversion efficiency of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View BBOT share price today for real-time trading data and today's change.
BridgeBio Oncology Therapeutics, Inc. Cash Flow Conversion Ratio Explained
BridgeBio Oncology Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BridgeBio Oncology Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see BridgeBio Oncology Therapeutics, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Climb Global Solutions
NASDAQ:CLMB
|
-0.102x |
|
Lithium Royalty Corp
TO:LIRC
|
-0.001x |
|
Jikai Equipment Manufacturing Co Ltd
SHE:002691
|
-0.008x |
|
Urbana Corporation
TO:URB-A
|
-0.006x |
|
Franklin Universal Closed Fund
NYSE:FT
|
0.027x |
|
Vietnam Container Shipping JSC
VN:VSC
|
-0.101x |
|
Wismilak Inti Makmur Tbk
JK:WIIM
|
0.040x |
|
Hexagon Purus As
OL:HPUR
|
-1.040x |
Annual Cash Flow Conversion Efficiency for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. Review BBOT financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $411.10 Million | $-113.89 Million | -0.277x | -6745.05% |
| 2024-12-31 | $188.72 Million | $-763.82K | -0.004x | -100.00% |
| 2023-12-31 | $-63.57K | $-52.08 Million | 819.252x | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more